In contrast, AFM28 induced ADCC irrespective of CD64 or CD32 expression, indicating that AFM28 retained ADCC efficacy against CD123+ AML cell lines co-expressing CD64 and CD32. This evidence concerns the gene FCGR2A and acute myeloid leukemia.